Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M |
| Total Depreciation and Amortization | 6.00K | 13.00K | 15.00K | 16.00K | 15.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.92M | 1.08M | 3.45M | 2.32M | 2.60M |
| Change in Net Operating Assets | -2.06M | -6.74M | 4.60M | 10.77M | -5.89M |
| Cash from Operations | -39.47M | -37.89M | -28.87M | -30.17M | -45.49M |
| Capital Expenditure | -- | -15.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.94M | -103.47M | -150.51M | -42.88M | -92.88M |
| Cash from Investing | -44.94M | -103.49M | -150.51M | -42.88M | -92.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24.27M | 97.01M | 295.22M | 9.88M | 189.29M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.00K | -305.00K | -29.00K | -47.00K | -10.00K |
| Cash from Financing | 24.27M | 96.70M | 295.19M | 9.83M | 189.28M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.14M | -44.68M | 115.81M | -63.22M | 50.92M |